SHANGHAI, March 13,
2023 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD)
("Zhongchao" or the "Company"), a platform-based internet
technology company offering services to patients with oncology and
other major diseases, today announced the survey results of bone
marrow patient services provided by Zhongxin Health, a platform of
Shanghai Zhongxin Medical Technology Co., Ltd., one of the
companies that Zhongchao consolidates the financial and operations
results with through a certain contractual arrangements. The survey
revealed that approximately 80.6% of patients gave full marks to
the patient services provided by Zhongxin Health platform.
Zhongxin Health provides rehabilitation knowledge, medication
management, medication assistance, out-of-hospital rehabilitation
support, and other services to patients with cancer and rare
disease patients majorly through WeChat Mini Program and WeChat
Public Account channels, helping patients improve treatment effects
and quality of life.
Bone marrow cancer is one of the top three blood system
malignancies in China. With more
treatment options available in recent years, patients' survival
rates have improved, and their demands for disease management have
increased. The survey was conducted in December 2022, with more than 400 bone marrow
cancer patients from 139 cities in China using Zhongxin Health platform
participating. Among them, approximately 24.5% of patients were
diagnosed within the past one year, while approximately 45.8% of
patients had been diagnosed for one to three years.
The survey results indicate that majority of the patients found
it useful and were satisfied with the services provided via
Zhongxin Health platform. Approximately 75.5% of bone marrow cancer
patients improved their understanding of the disease through the
services provided by the Zhongxin Health platform, while
approximately 59.1% of patients increased their confidence in
treatment. The average score for patient service evaluations on a
scale of 1 to 5 was 4.69, with approximately 80.6% of patients
giving the highest rating, and approximately79.0% of patients
willing to recommend the platform to more patients.
Additionally, the survey results reflected that there is still a
huge market demand for bone marrow cancer patient services.
Approximately 67.8% of patients like to obtain knowledge about drug
treatment, transplantation, adverse reaction management and others
through the platform, approximately 65.2% of patients hope to learn
about medical insurance and policy related information,
approximately 51.6% of patients are interested in diet and
nutrition guidance, approximately 43.2% of patients like to obtain
home care knowledge, approximately 35.5% of patients are interested
in exercise guidance, and approximately 22.7% of patients hope to
hear about other patients' stories.
Most of the content that patients are interested in can be found
on the WeChat Mini-Program of Zhongxin Health. Zhongchao looks
forward that Zhongxin Health will further improve patient services
based on patient recognition and feedbacks to meet patients' needs.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "we are pleased to see
that the services provided by Zhongxin Health have been recognized
by the majority of bone marrow cancer patients on the platform. We
will continue to improve our services to provide patients with
comprehensive and high-quality services and supports."
About Zhongchao Inc.
Zhongchao Inc. is an offshore holding company incorporated in
the Cayman Islands. It conducts
operations in China through the
contractual arrangements between its wholly owned subsidiary and
PRC operating entities. Zhongchao Inc. is a platform-based internet
technology company offering services to patients with oncology and
other major diseases. The PRC operating entities provide online
healthcare information, professional training and educational
services to healthcare professionals under their "MDMOOC" platform
(www.mdmooc.org), offer patient management services in the
professional field of tumor and rare diseases through Zhongxin,
offer internet healthcare services through Zhixun Internet
Hospital, and pharmaceutical services through Xinjiang Medical and
operate an online information platform, Sunshine Health Forums, to
general public. More information about the Company can be found at
its investor relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's future
business development; product and service demand and acceptance;
changes in technology; economic conditions; the growth of the
professional training and educational services market in
China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions in
China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and severity
of the recent coronavirus outbreak, including its impacts across
our business and operations. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward–looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 13901629242
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-releases-survey-results-for-bone-marrow-cancer-patient-services-with-more-than-80-patients-indicating-full-satisfaction-301769762.html
SOURCE Zhongchao Inc.